期刊文献+

水蛭源性类胰蛋白酶抑制剂表达载体的构建与表达

Cloning and expression of leech derived tryptase inhibitor
下载PDF
导出
摘要 目的:构建水蛭源性类胰蛋白酶抑制剂(leech derived tryptase inhibitor,LDTI)原核表达载体,并在大肠埃希菌[BL21(DE3)]中高效表达重组蛋白。方法:以含有目的核酸序列的质粒为模板,通过PCR技术扩增出LDTI蛋白编码序列,构建含目的片段的T克隆载体以及原核表达载体pET28a-LDTI重组质粒亚克隆,进行限制性内切酶双酶切鉴定和核酸序列分析,然后将该质粒转化大肠埃希菌BL21(DE3),IPTG诱导,以Tricine-SDS-PAGE和蛋白质印迹方法分析和鉴定重组蛋白的表达。结果:成功构建了水蛭源性类胰蛋白酶抑制剂原核表达载体pET28a-LDTI,并获得相应的融合蛋白;本实验证明,LDTI在大肠埃希菌工程菌中高效表达,在温度为33℃,IPTG浓度为0.7 mmol,诱导时间为1 h,所表达的目的蛋白约占菌体总蛋白的15%左右。结论:成功构建了LDTI原核表达载体并使其在原核系统中高效表达,为进一步研究水蛭源性类胰蛋白酶抑制剂的生化特性和生物学功能奠定了良好的基础。 Objective: To construct the prokaryotic expression vector of LDTI gene and express LDTI protein in E. coli[ BL21 (DE3) ]. Methods: A 141 bp fragment of the LDTI gene was amplified by PCR technique from the template of the plasmid containing LDTI gene,then it was cloned into T vector.After amplified and digested with restricted enzyme,the target fragment was subcloned into plasmid pET28a,the recombinant plasmid was transferred into E.coli Jm109.The fragment was identified by restricted enzyme and nucleotide sequencing.The recombinant expression plasmid containing LDTI gene was transformed into E.coli BL21(DE3) and the target protein expression was induced by isopropyl-B-D-thiogalactopyranoside (IPTG) and confirmed by Tricine-SDS-PAGE and Western blot.Results:The recombinant plasmid of pET28a-LDTI was obtained by PCR and identified by sequencing.The target protein was expressed abundantly in E.coli BL21(DE3) and the yield of LDTI protein was accounted for approximately 15% of germ proteins after one hour's induction by 0.7mmol/L IPTG at 33℃.Conclusion:pET28a-LDTI was successfully constructed and can highly express objective protein in BL21(DE3),which will further help to the bioactivity of LDTI studying.
出处 《江苏大学学报(医学版)》 CAS 2008年第5期410-412,415,I0002,共5页 Journal of Jiangsu University:Medicine Edition
关键词 构建 原核表达 水蛭源性类胰蛋白酶抑制剂 construction prokaryotic expression leech derived tryptase inhibitor
  • 相关文献

参考文献9

  • 1谢华,何韶衡.特异性类胰蛋白酶抑制剂双苯甲脒对肥大细胞分泌的调控作用[J].细胞与分子免疫学杂志,2003,19(1):100-102. 被引量:20
  • 2Caughey GH. Mast cell tryptases and chymases in inflammation and host defense [ J J. Immunol Rev, 2007,217 (1) :141 -154.
  • 3Arolas JL, Bronsoms S, Aviles FX, et al. Oxidative folding of leech-derived tryptase inhibitor via native disulfide-bonded intermediates [ J ]. Antioxid Redox Signal, 2008,10(1) :77 -85.
  • 4Mark B, Abelson MD, Andrea Leonardi MD, et al. The mechanisms, diagnosis and treatment of allergy [ J ]. J Rev Ophth, 2002,9 (4) :75 - 80.
  • 5Church MK, Bradding P, Walls AF, et al. Human mast cells and basophils [ M ] // ABkay. allergy and allergic diseases Blackwell : Oxford, 1997 : 149 - 170.
  • 6王贤杰,何韶衡.含胍基类肥大细胞类胰蛋白酶抑制剂的特性及功能研究进展[J].中国药学杂志,2004,39(10):727-730. 被引量:1
  • 7Caughey GH, Raymond WW, Blount JL, et al. Characterization of human gmmatry-ptases, novel members of the chromosome 16p mast cell tryptase and prostasin gene families[ J ]. J Immunol, 2000,164 ( 12 ) : 6566 -6575.
  • 8Guida M, Riedy M, Lee D, et al. Characterization of two highly polymorphic human tryptase loci and comparison with a newly discovered monkey tryptase ortholog [ J ]. Pharmacogenetics ,2000,10 (5) :389 - 396.
  • 9谢华,何韶衡,程明华,傅意玲.类胰蛋白酶抑制剂对人大肠肥大细胞组胺释放的影响[J].细胞与分子免疫学杂志,2004,20(6):678-681. 被引量:5

二级参考文献49

  • 1[1]Church MK, Bradding P, Walls AF, et al. Human mast cells and basophils. In allergy and allergic diseases[M]. by AB Kay, Blackwell, Oxford. 1997:149-170.
  • 2[2]Okayama Y, Church MK. Comparison of the modulatory effect of ketotifen, sodium cromoglycate, procaterol and salbutamol in human skin, lung and tonsil mast cells[J]. Int Arch Allergy Appl Immunol, 1992, 97:216-222.
  • 3[3]Okayama Y, Benyon RC, Lowman MA, et al. In vitro effects of H1-antihistamine and PGD2 release from mast cells of human lung, tonsil and skin[J]. Allergy, 1994, 49:246-253.
  • 4[4]Butchers PR, Vardey CJ, Johnson M. Salmeterol: a potent and long-acting inhibitor of inflammatory mediator release from human lung[J]. Br J Pharmacol, 1991, 104:672-676.
  • 5[5]Naclerio R, Kagey-Sobotka MA, Lichtenstein LM, et al. Terfenadine, an H1 antihistamine, inhibits histamine release in vivo in the human[J]. Am Rev Respir Dis, 1990, 142:167-171.
  • 6[6]He S, Gaca MDA, Walls AF. A role for tryptase in the activation of human mast cells: modulation of histamine release by tryptase and inhibitors of tryptase[J]. J Pharmacol Exp Ther, 1998, 286:289-297.
  • 7[7]Clark JM, Abraham WM, Fishman CE, et al. Tryptase inhibitors block allergen-induced airway and inflammatory responses in allergic sheep[J]. Am J Respir Crit Care Med, 1995, 152:2076-2083.
  • 8[8]Burgess LE, Newhouse BJ, Ibrahim P, et al. Potent selective nonpeptidic inhibitors of human lung tryptase[J]. Proc Natl Acad Sci USA, 1999, 96:8348-8352.
  • 9[9]Buckley MG, Variend S, Walls AF. Elevated serum concentrations of beta-tryptase, but not alpha-tryptase, in sudden infant death syndrome (SIDS). An investigation of anaphylactic mechanisms[J]. Clin Exp Allergy, 2001, 11:1696-1704.
  • 10[10]Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from dispersed lung mast cells by anti-allergic drugs and salbutamol[J]. Br J Pharmacol, 1987, 90:421-429.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部